is indicated for the treatment of HIV-1 infection in:

(1) patients 12 years of age and older with no antiretroviral treatment history and with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy, and

(2) in certain virologically suppressed (HIV-1 RNA < 50 copies/ml) patients.

Manufactured by: Gilead Sciences. Inc

Active Ingredient(s): Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil Fumarate.

Dosage Form:  Tablets, Oral

Strength:  Each tablet contains 200 mg of Emtricitabine (FTC), 27.5 mg of Rilpivirine hydrochloride (equivalent to 25 mg of Rilpivirine) and 300 mg of Tenofovir disoproxil fumarate (Tenofovir DF or TDF, equivalent to 245 mg of Tenofovir disoproxil).

FDA approved: December 13, 2013

More information about Complera:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202123s000lbl.pdf

www.gilead.com/~/media/files/pdfs/medicines/hiv/complera/complera_pi_old.pdf